Oncolytics Biotech (ONCY) Payables (2009 - 2026)

Oncolytics Biotech (ONCY) has reported Payables for 18 consecutive years, with $3.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables fell 25.22% year-over-year to $3.4 million in Q2 2026; TTM through Jun 2026 was $3.4 million, a 25.22% decrease from a year earlier, with the FY2025 full-year figure at $3.6 million, down 15.06% from the prior year.
• Payables was $3.4 million for Q2 2026 at Oncolytics Biotech, down from $3.6 million in the prior quarter.
• Over five years, Payables peaked at $7.3 million in Q3 2023 and troughed at $1.7 million in Q1 2022.
• A 5-year average of $3.4 million and a median of $3.3 million in 2024 frame the typical range for Payables.
• Across the five-year window, Payables jumped 180.89% in 2023 and tumbled 55.15% in 2024, its largest moves.
• Over 5 years, Payables stood at $2.7 million in 2022, then fell by 4.49% to $2.6 million in 2023, then soared by 57.48% to $4.1 million in 2024, then retreated by 13.33% to $3.6 million in 2025, then retreated by 4.91% to $3.4 million in 2026.
• The last three Payables figures came in at $3.4 million (Q2 2026), $3.6 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.